(3) We chose to concentrate our studies on ranibizumab, which is FDA approved for AMD, while also studying bevacizumab (off-label use) and FDA approved aflibercept as additional anti-VEGF agents, which are also used for AMD treatment. This evidence concerns the gene VEGFA and age-related macular degeneration.